I'm curious about all the red tape surrounding this, but once a drug is approved a doctor, if they have good reason to, can take liberties to use it for a different type of cancer. I don't believe there is any rule saying you're only allowed to use DCVax-L when its GBM. We are also talking about a drug with a near-perfect safety profile so you can take more liberties in the way you prescribe the treatment.
If DCVax-L is effective for all solid tumors then "to-da-moon."
Market Data 
Markets 
AI
